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Circulating Endothelial Progenitor Cells in Cardiovascular Outcomes
Werner N, Kosiol S, Schiegle T, et al. N Engl J Med 2005;353:99-1007.
Conclusion: Endothelial progenitor cells positive for CD-34 and
kinase domain receptor (KDR) predict occurrence of death from cardiovas-
cular causes and cardiovascular events.
Summary: Endothelial progenitor cells can differentiate into endothe-
lial cells and proliferate. They may be candidates for mediating vascular
regeneration. These cells, derived from the bone marrow, are thought to
support vascular endothelium integrity. Levels of endothelial progenitor
cells correlate inversely with cardiovascular risk factors. The authors sought
to study the prognostic value associated with circulating endothelial progen-
itor cells.
Endothelial progenitor cells positive for CD-34 and KDR were deter-
mined using flow cytometry. Five hundred and nineteen patients with
coronary artery disease confirmed by angiography were studied. After twelve
months of follow-up, association between death from cardiovascular causes,
the occurrence of a first major cardiovascular event (defined as myocardial
infarction, hospitalization, revascularization, or death from cardiovascular
cause), revascularization, hospitalization, and death from all causes was
correlated with baseline levels of endothelial progenitor cells.
Two hundred and fourteen patients had a first major cardiovascular
event, 43 participants died, with 23 of these deaths from cardiovascular
causes. Adjusting for age, vascular risk factors, sex, and other variables
relevant to cardiovascular disease, increased levels of endothelial progenitor
cells were associated with a reduced risk of a first major cardiovascular event
(Hazard ratio (HR) 0.74; 95% confidence interval (CI) 0.62 to 0.89; P 
.002), death from cardiovascular causes, (HR 0.31; 95% CI 0.16 to 0.63;
P  .001), hospitalization (HR 0.76; 95% CI 0.63 to 0.94; P  .01), and
revascularization (HR 0.77; 95% CI 0.62 to 0.95; P  .02). Myocardial
infarction and death from all causes were not predicted by endothelial
progenitor-cell levels.
Comment: The role of endothelial progenitor cells in rejuvenation of
vascular endothelium is currently an area of intensive investigation. It
appears these immature cells may modify the pathogenesis of atherosclerotic
disease. Measurement of endothelial progenitor cells may improve risk
stratification in patients with cardiovascular disease.
Evaluation of the Safety and Effectiveness of Renal Artery Stenting
After Unsuccessful Balloon Angioplasty: The ASPIRE-2 Study
Rocha-Singh K, Jaff MR, Rosenfield K, and the ASPIRE-2Trial Investigators.
J Am Coll Cardiol 2005;46:776-83.
Conclusion: Balloon-expandable stents in hypertensive patients with
ostial renal artery atherosclerotic stenosis can have a beneficial impact on
hypertension when initial transluminal angioplasty is unsuccessful.
Summary: The authors sought to define safety and durability of renal
artery stents following suboptimal or failed renal artery angioplasty when
renal vascular hypertension was suspected. This was a non randomized study
that enrolled 208 patients with either primary or restenontic (70%) ostial
renal artery stenosis. All patients underwent placement of a balloon-expandable
stent following an unsuccessful transluminal angioplasty. Unsuccessful
transluminal renal artery angioplasty was defined as 50% residual stenosis,
flow limiting dissection, or a persistent trans-lesion pressure gradient. Pri-
mary end point was restenosis at 9 months as determined by angiogram or
duplex scanning. Secondary end points included blood pressure, cumulative
adverse events, renal function, and target lesion revascularization at 24
months.
In 80.2% of cases, placement of the stent was immediately successful
(n  182 of 227). Nine month restensosis rate was 17.4%. Systolic blood
pressure decreased from 168  25 mm/Hg at baseline to 149  24
mm/Hg at 9 months and 149  25 mm/Hg at 24 months (P  .001). At
24 months, the cumulative rate of major adverse events was 19.7%. Serum
creatinine concentrations were unchanged from baseline values at both 9
and 24 months.
Comment: The study is limited by its retrospective nature and lack of
controls in that no patients were treated with medical therapy or simple
balloon angioplasty alone. In addition, primary stenting of renal artery ostial
lesions is currently routine. The study provides reasonable information
regarding recurrent stenosis in a sub group of patients undergoing renal
artery stenting. Overall, however, it is of little relevance to modern practice.
Risk of Major Haemorrhage in Patients After Infra-Inguinal Venous
Bypass Surgery: Therapeutic Consequences. The Dutch BOA (Bypass
Oral Anticoagulants or Aspirin) Study
Ariesen NJ, Tangelder MJD, Lawson JA, and the Dutch Bypass Oral
Anticoagulants or Aspirin (BOA) Study. Eur J Vasc Endo Surg 2005;30:
154-159.
Conclusion: Even considering the risk of hemorrhage, it is recom-
mended patients following peripheral venous bypass surgery be routinely
treated with oral anticoagulants.
Summary: The Dutch Bypass Oral Anticoagulants or Aspirin (BOA)
study indicated oral anticoagulants were more effective than aspirin in
preventing occlusion of lower extremity vein bypass grafts (Hazard Ratio)
0.69, 95% CI 0.54-0.88. Lancet 2000;355:1186-1187). In the BOA study,
however, there was two-fold increase risk of bleeding complications in
patients treated with oral anticoagulants following peripheral bypass surgery
(HR 1.96, 95% CI 1.42-2.71). In this study, the authors developed a model
to identify patients treated with anticoagulation who are at risk of major
hemorrhage. They also included in their model an estimation of whether
hemorrhage could be prevented by the use of aspirin rather than by the use
of oral anticoagulants.
Data of patients in the BOA study was reanalyzed with Cox regression
techniques. In the BOA study, there were 1,326 patients randomized to oral
anticoagulants and 1,324 randomized to aspirin.
There was an increased risk of major hemorrhage in patients on
anticoagulants associated with systolic blood pressure greater than 140
mm/Hg (HR 1.62), diabetes mellitus (HR 1.60), and age 75 years
(HR 2.77). Stratifying patients according to risks quartiles; if patients in
the highest risk quartile had received aspirin rather than anticoagulants,
the number of patients with major hemorrhage would, according to the
model, have been reduced from 46 to 22. This would have been
associated with no major changes in ischemic events or graft occlusions.
In the subgroup of patients with venous bypasses, a similar analysis
indicated major hemorrhages would be reduced from 27 to 13 patients,
but at a cost of 7 more mostly fatal ischemic events and 17 more graft
occlusions.
Comment: The BOA study is widely known and widely quoted but
thus far its findings have had little influence on the treatment of patients
with peripheral vein bypass grafts. Part of the lack of acceptance of the
BOA recommendations undoubtedly has to do with the increased hem-
orrhage rate with the use of anticoagulants. This analysis suggests that
even with the increased hemorrhage rates using oral anticoagulants,
patients with vein bypasses still benefit overall with oral anticoagulants
compared to aspirin. Although the authors’ model is interesting, this type
of retrospective analysis, in itself, is not going to convince many to utilize
oral anticoagulants as routine prophylaxis against vein bypass graft
occlusion.
Is Duplex Surveillance of Value After Leg Vein Bypass Grafting? The
Principle Results of the Vein Graft Surveillance Randomized Trial
(VGST)
Davies AH, Howdon AG, Thompson SG, and the VGST Participants.
Circulation 2005;112:1985-991.
Conclusion: Intensive postoperative graft surveillance with duplex
scanning following lower extremity vein bypass graft operations does not
result in lower amputation rates than a simple program of clinical surveil-
lance.
Summary: This was a multicenter, randomized, prospective, con-
trolled clinical trial. There were 594 patients with a patent vein graft 30 days
following surgery. These patients were randomized to either clinical follow
up alone or a duplex follow up program with studies at 6 weeks and then 3,
6, 9, 12, and 18 months postoperatively. Approximately 2/3 of the grafts
were placed for critical ischemia with 2/3 of the distal anastomoses to the
popliteal artery either above or below the knee. Approximately 1/3 of the
patients in each group had diabetes and the median age was 70 years in each
group. Ipsilateral greater saphenous vein was used in 92% of the clinical
follow up group and 94% of the duplex follow up group.
There are no differences in the clinical and duplex surveillance groups
with respect to amputation rates (7% for each group) or vascular mortality
(3% v 4%) at 18 months. There were more stenoses at 18 months in the
clinical group (19% v 12% P  .04). Primary patency, primary assisted
patency, and secondary patency were similar in the clinical group (69%, 75%,
and 80% and the duplex group 67%, 76%, and 79%). There were no apparent
196
differences in health related quality of life but the duplex surveillance
program was more costly by an average of 495 pounds more per patient.
Comment: Vein graft stenoses develop more frequently in longer
grafts (ie tibial distal targets), grafts placed for limb salvage, disadvantaged
grafts (composite grafts, arm vein grafts) and perhaps in patients undergoing
repeat procedures. In this paper most of the patients probably had primary
operations as evidenced by the high level of use of ipsilateral greater
saphenous vein, 2/3 of the anastomoses were to the popliteal artery, and
amputation rates appeared to have been analyzed using both claudicants and
limb salvage patients for the life table, a bit of a no-no. In short, if ever there
were a group of patients who are unlikely to benefit from duplex surveillance,
this is the group. This paper should not lead one to abandon vascular
laboratory duplex surveillance for vein grafts potentially at increased risk for
stenosis as noted above. However, the data does suggest that when a vein
graft is placed to a popliteal artery using ipsilateral saphenous vein, duplex
surveillance may not be of much benefit in reducing amputations over the
short run.
Suboptimal Intensity of Risk Factor Modification in Peripheral Arterial
Disease (PAD)
Oka RK, Umoh E, Szuba A, et al. Vasc Med 2005;10:91-6.
Conclusion: There is suboptimal medical management of atheroscle-
rotic risk factors in patients with peripheral arterial disease (PAD).
Summary: The PARTNERS study (PAD Awareness, Risk and Treat-
ment) indicated that PADwas under recognized in primary care practice and
only 60% of patients with PADwere receiving lipid lowering therapy (JAMA
2001;286:1317-24). This study sought to determine if practice guidelines
for patients with cardiovascular disease, developed after publication of
PARTNERS, have effected current community management of PAD.
The authors recruited via a media campaign conducted in a large
northern California urban area patients with leg pain that limited their
walking. Respondents were screened by telephone and, if eligible, offered
PAD assessment. Eligibility criteria included age 50 years with symptom-
atic PAD. PAD was defined as exertional leg pain with an ankle brachial
index 0.9. For patients with diabetes, PAD was defined as a toe pressure
of30mmHg. Patients must have been able to walk for 2minutes or 50 feet
on an exercise treadmill and have been on a stable medication regimen.
Patients with rest pain, ulceration or gangrene were excluded. Also excluded
were patients with recent myocardial infarction, Type I diabetes, and active
malignancy. Treatment and risk factor profiles were determined by self
reported medical history and current medication lists. Patients were
evaluated as to whether or not they met current treatment guidelines for
lipids, hypertension, and diabetes. With respect to lipids, an LDL cho-
lesterol 100 mg/dl was considered to have met therapeutic guidelines.
Hypertension was defined as a systolic blood pressure140 mmHg and a
diastolic blood pressure 90 mmHg. Hemoglobin A1c levels (HgbA1c)
7% indicated suboptimal glycemic control.
There were 101 subjects in this study. Dyslipidemia was recognized in
56.4%. In dyslipidemic subjects there was suboptimal therapy in 52.6%. In
addition, 20.8% of the sample were previously unrecognized cases.
A history of hypertension was reported in 54.5% of the study sample.
Management of systolic blood pressure was sub-optimal in 74.5% of hyper-
tensive subjects. Systolic hypertension had been previously unrecognized in
13.9% of the study subjects. Hypertensive patients were found a 81%
utilization rate of antihypertensive medication. Patients on mono versus
triple therapy for hypertension exhibited no significant differences in systolic
or diastolic blood pressures.
Diabetes was reported in 26.7% of the patients. HgbA1c was 7.9 1.9
mg/dl. Glycemic control was felt to be suboptimal in 57% of patients (mean
HgbA1c  8.7  1.8 mg/dl).
Sixty-two percent of the study population was on anti-platelet therapy.
Anticoagulation therapy was employed in 15%. About 35% of subjects (n 
36) were not taking anticoagulant or anti-platelet therapy. No patients
appeared to have had a contraindication to anti-platelet therapy.
Comment: The study is small and therefore subject to Type II
statistical error. Nevertheless, the results are similar to PARTNERS and
indicate suboptimal management of risk factors in patients with PAD. It
is clear one publication, the PARTNERS publication, has not had a
dramatic impact on primary care practice with respect to management of
PAD. Meaningful changes in management of PAD risk factors will only
occur after intensive promulgation of treatment goals for patients with
PAD.
Use of Quantitative Magnetic Resonance Angiography to Stratify
Stroke Risk in Symptomatic Vertebrobasilar Disease
Amin-Hanjani S, Du X, Zhao M, et al. Stroke 2005;36:1140-5.
Conclusion: Quantitative magnetic resonance angiography (QMRA)
can stratify risk for stroke in patients with symptomatic vertebrobasilar
disease (VBD).
Summary: Phase-contrast QMRA is a magnetic resonance technique
for noninvasively measuring blood flow in intracranial vessels (Magn Reson
Imaging 2000;18:697-706). The authors used a standard protocol that
included QMRA to evaluate patients with symptomatic VBD. QMRA was
used to stratify patients according to the presence or absence of flow
compromise distal to the site of VBD. Flow was considered compromised in
specific vessels if it was reduced greater than 20% of the lower limit of normal
baseline value for that vessel. Flow compromise was evaluated in the basilar
and posterior cerebral arteries. The basilar artery was designated as having
reduced flow if flow measurements were less than 12 mL/min, and the
posterior cerebral arteries were designated as having reduced flow if flow
measurements were less than 40 mL/min. Patients with low distal flows
were then offered either surgical or endovascular intervention, and other
patients received standard medical therapy. The article reports the results of
this protocol for patients treated from 1998 to 2003. There were 50 patients
subjected to the protocol and 47 available for follow-up over a mean interval
of 28 months. Kaplan-Meier curves were used to calculate stroke and
stroke-free survival at 2 years and a combination of stroke-free survival and
freedom from transient ischemic attacks at 2 years.
Patients with normal distal flow (n  31) had event-free survivals of
100% and 96%, respectively. At 2 years patients with low distal flows had a
71% event-free survival with respect to stroke and a 53% event-free survival
with respect to the combined end point of stroke and transient ischemic
attack. Patients with low distal flows had a higher risk of recurrent ischemia
(P  .003). Twelve patients with low flow underwent treatment and had
82% event-free survival. With Cox proportional analysis, flow status effected
event-free survival independently of covariants.
Comment: Patients with symptomatic VBD can be offered interven-
tion for large-vessel stenoses that are believed to be hemodynamically
significant. However, collateralization in the posterior circulation can be
extensive, and the presence of hemodynamically significant lesions in the
proximal vessels does not necessarily result in diminished posterior circula-
tion blood flow. QMRAmay provide a method of selection for intervention
for those patients with VBD who are most likely to benefit from an open or
endovascular surgical procedure. This article may represent a major step
forward for the selection of patients for vertebral artery reconstruction.
Cilostazol Prevents the Progression of Symptomatic Intracranial Arterial
Stenosis: The Multicenter Double-Blind Placebo-Controlled Trial of
Cilostazol in Symptomatic Intracranial Arterial Stenosis
Kwon SU, Jo Y-J, Koo J-S, et al. Stroke 2005;36:782-786.
Conclusion: Cilostazol appears to prevent progression of intercranial
arterial stenoses that have previously been associated with symptoms.
Summary: Cilostazol appears to have a number of pleotrophic effects
other than improvement of intermittent claudication. It has been shown to
decrease restenosis after coronary angioplasty and stenting and reduce
growth rate of carotid intimal medial thickness in patients with diabetes. In
this trial, the authors investigated the ability of Cilostazol to prevent pro-
gression of intercranial arterial stenoses associated with symptoms. The
patients enrolled were 35-80 years of age and had a recent ischemic stroke
within two weeks that was felt to be associated with stenosis in the M1
segment of the middle cerebral artery or stenosis of the basilar artery.
Patients were required to have MRA evidence of stenosis in the noted
arteries as well as acute ischemic changes onMRI. Participants were followed
at 1, 3, 5, and 6 months. Primary outcome was progression of stenosis in
symptomatic vessels at 6 months. Stenosis was classified into 1 of 5 grades
based on MR findings. Progression was defined as worsening of stenosis by
1 or more grades and regression of stenosis was defined as improvement of
stenosis by 1 or more grades compared to the initial MRA study. Patients
were also assessed with transcranial Doppler examinations.
From February 2000, to July 2003, 135 patients were enrolled in the
trial. Sixty-seven were randomly assigned to Cilostazol and 68 assigned to
receive placebo. All patients in both groups also received 100mg of aspirin
daily.
Baseline patient characteristics and location of intercranial lesions re-
sulting in symptoms were similar in the two groups. During follow up there
were no strokes or transient ischemic attacks and two participants in each
group had an acute coronary event. There was one unexplained death in each
group. There were 20 dropouts in the Cilostazol group (29.9%), and 14
dropouts in the placebo group (20.6%).
Progression of a symptomatic intercranial arterial stenosis occurred in 3
of the 45 patients available for follow up in the Cilostazol group (6.7%) and
15 of the 52 patients available for follow up in the placebo group (28.8%).
Regression of the intercranial lesion producing symptoms was noted in
24.4% of the Cilostazol group and 15.4% of the placebo group. Overall
progression of an intercranial arterial stenosis associated with symptoms was
less frequent in the Cilostazol group than the placebo group (p  0.008).
Transcranial Doppler studies also indicated progression to be less frequent in
the Cilostazol group than the placebo group (p 0.001). Progression rates
of intercranial arterial lesions that were not associated with symptoms were
not different between the two groups (p  0.384).
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